Previous close | 4.6500 |
Open | 4.6500 |
Bid | 2.5000 |
Ask | 6.3000 |
Strike | 1.00 |
Expiry date | 2025-01-17 |
Day's range | 4.6500 - 4.6500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy co
uniQure ( NASDAQ:QURE ) First Quarter 2024 Results Key Financial Results Revenue: US$8.49m (up 59% from 1Q 2023). Net...
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 20